Insights into Potential Targets for Therapeutic Intervention in Epilepsy
Epilepsy is a chronic brain disease that affects approximately 65 million people worldwide. However, despite the continuous development of antiepileptic drugs, over 30% patients with epilepsy progress to drug-resistant epilepsy. For this reason, it is a high priority objective in preclinical researc...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/22/8573 |
id |
doaj-a3d7abb82887485e9ace16e9a77f20ee |
---|---|
record_format |
Article |
spelling |
doaj-a3d7abb82887485e9ace16e9a77f20ee2020-11-25T04:06:01ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-11-01218573857310.3390/ijms21228573Insights into Potential Targets for Therapeutic Intervention in EpilepsyCecilia Zavala-Tecuapetla0Manola Cuellar-Herrera1Hiram Luna-Munguia2. Laboratory of Physiology of Reticular Formation, National Institute of Neurology and Neurosurgery-MVS, Insurgentes Sur 3877, La Fama, 14269 Mexico City, Mexico. Epilepsy Clinic, Hospital General de México Dr. Eduardo Liceaga. Dr. Balmis 148, Doctores, 06720 Mexico City, Mexico. Departamento de Neurobiologia Conductual y Cognitiva, Instituto de Neurobiologia, Campus UNAM-Juriquilla, Universidad Nacional Autonoma de Mexico, 76230 Queretaro, MexicoEpilepsy is a chronic brain disease that affects approximately 65 million people worldwide. However, despite the continuous development of antiepileptic drugs, over 30% patients with epilepsy progress to drug-resistant epilepsy. For this reason, it is a high priority objective in preclinical research to find novel therapeutic targets and to develop effective drugs that prevent or reverse the molecular mechanisms underlying epilepsy progression. Among these potential therapeutic targets, we highlight currently available information involving signaling pathways (Wnt/β-catenin, Mammalian Target of Rapamycin (mTOR) signaling and zinc signaling), enzymes (carbonic anhydrase), proteins (erythropoietin, copine 6 and complement system), channels (Transient Receptor Potential Vanilloid Type 1 (TRPV1) channel) and receptors (galanin and melatonin receptors). All of them have demonstrated a certain degree of efficacy not only in controlling seizures but also in displaying neuroprotective activity and in modifying the progression of epilepsy. Although some research with these specific targets has been done in relation with epilepsy, they have not been fully explored as potential therapeutic targets that could help address the unsolved issue of drug-resistant epilepsy and develop new antiseizure therapies for the treatment of epilepsy.https://www.mdpi.com/1422-0067/21/22/8573epilepsyseizuresdrug-resistant epilepsyantiseizure efficacyantiepileptogenic effectneuroprotective effect |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cecilia Zavala-Tecuapetla Manola Cuellar-Herrera Hiram Luna-Munguia |
spellingShingle |
Cecilia Zavala-Tecuapetla Manola Cuellar-Herrera Hiram Luna-Munguia Insights into Potential Targets for Therapeutic Intervention in Epilepsy International Journal of Molecular Sciences epilepsy seizures drug-resistant epilepsy antiseizure efficacy antiepileptogenic effect neuroprotective effect |
author_facet |
Cecilia Zavala-Tecuapetla Manola Cuellar-Herrera Hiram Luna-Munguia |
author_sort |
Cecilia Zavala-Tecuapetla |
title |
Insights into Potential Targets for Therapeutic Intervention in Epilepsy |
title_short |
Insights into Potential Targets for Therapeutic Intervention in Epilepsy |
title_full |
Insights into Potential Targets for Therapeutic Intervention in Epilepsy |
title_fullStr |
Insights into Potential Targets for Therapeutic Intervention in Epilepsy |
title_full_unstemmed |
Insights into Potential Targets for Therapeutic Intervention in Epilepsy |
title_sort |
insights into potential targets for therapeutic intervention in epilepsy |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2020-11-01 |
description |
Epilepsy is a chronic brain disease that affects approximately 65 million people worldwide. However, despite the continuous development of antiepileptic drugs, over 30% patients with epilepsy progress to drug-resistant epilepsy. For this reason, it is a high priority objective in preclinical research to find novel therapeutic targets and to develop effective drugs that prevent or reverse the molecular mechanisms underlying epilepsy progression. Among these potential therapeutic targets, we highlight currently available information involving signaling pathways (Wnt/β-catenin, Mammalian Target of Rapamycin (mTOR) signaling and zinc signaling), enzymes (carbonic anhydrase), proteins (erythropoietin, copine 6 and complement system), channels (Transient Receptor Potential Vanilloid Type 1 (TRPV1) channel) and receptors (galanin and melatonin receptors). All of them have demonstrated a certain degree of efficacy not only in controlling seizures but also in displaying neuroprotective activity and in modifying the progression of epilepsy. Although some research with these specific targets has been done in relation with epilepsy, they have not been fully explored as potential therapeutic targets that could help address the unsolved issue of drug-resistant epilepsy and develop new antiseizure therapies for the treatment of epilepsy. |
topic |
epilepsy seizures drug-resistant epilepsy antiseizure efficacy antiepileptogenic effect neuroprotective effect |
url |
https://www.mdpi.com/1422-0067/21/22/8573 |
work_keys_str_mv |
AT ceciliazavalatecuapetla insightsintopotentialtargetsfortherapeuticinterventioninepilepsy AT manolacuellarherrera insightsintopotentialtargetsfortherapeuticinterventioninepilepsy AT hiramlunamunguia insightsintopotentialtargetsfortherapeuticinterventioninepilepsy |
_version_ |
1724432821121974272 |